Shanghai, PRC, June 5th, 2022 — OriCell Therapeutics Co., Ltd (OriCell) today reported the positive results from Phase I POLARIS study, an investigator-sponsored study evaluating Ori-CAR017, an autologous GPRC5D-directed CAR-T cell, in patients with relapsed/refractory multiple myeloma at American Society of Clinical Oncology(ASCO) annual meeting.
Shanghai, PRC, May 26, 2022—OriCell Therapeutics Co., Ltd (OriCell) today announced that an abstract detailing data from a Phase I study evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (POLARIS) will be presented an oral session at the upcoming 2022 ASCO Annual Meeting on Sunday, June 5th.
OriCell Therapeutics announced the newest data from a Phase I study evaluating OriCAR-017 in patients with Relapsed/Refractory Multiple Myeloma (POLARIS) has been accepted by the 27th European Hematology Association Congress, and detailed information will be presented in an oral seesion. OriCAR-017 is a CAR-T product with a novel target based on OriCell's independently developed Ori®Ab and Ori®CAR technology platform.
OriCell Therapeutics announced the newest clinical data of the independently developed product OriCell targeting Relapsed/Refractory Multiple Myeloma(RRMM) has been selected by ASCO 2022. The detailed data will be reported in oral presentation.
沪公网安备 31011502019994号